Quick Answer
Black Garlic Cardiometabolic Meta-Analysis has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 Metabolic Syndrome (MetS) is a cluster of metabolic disorders, including, among others, insulin resistance, dyslipidemia, and hypertension, that significantly increase the risk of developing type II diabetes (T2DM) and cardiovascular disease (CVDs) [,].
Key Takeaways
- 011 2 3 Metabolic Syndrome (MetS) is a cluster of metabolic disorders, including, among others, insulin resistance, dyslipidemia, and hypertension, that significantly increase the risk of developing type II diabetes (T2DM) and cardiovascular disease (CVDs) [,]. [Geddo Federica (2025)]
- 02Furthermore, the work examines the origin of SAC from garlic maturation, safety, and bioavailability, and the current evidence on its protective effects on several clinical outcomes associated with MetS. [Geddo Federica (2025)]
- 03It is clinically associated not only with an increased risk of developing T2DM, but also with accelerated atherosclerosis driven by chronic inflammation and vascular endothelial dysfunction, conferring a significantly increased cardiovascular risk []. [Geddo Federica (2025)]
- 04The first step in the management of MetS is lifestyle modification, with the adoption of a healthy diet and regular physical activity. [Geddo Federica (2025)]
The current Migaku evidence database contains 2 reusable source documents for Black Garlic Cardiometabolic Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation.
- 1 2 3 Metabolic Syndrome (MetS) is a cluster of metabolic disorders, including, among others, insulin resistance, dyslipidemia, and hypertension, that significantly increase the risk of developing type II diabetes (T2DM) and cardiovascular disease (CVDs) [,]. [Geddo Federica (2025); evidence level 3]
- Furthermore, the work examines the origin of SAC from garlic maturation, safety, and bioavailability, and the current evidence on its protective effects on several clinical outcomes associated with MetS. [Geddo Federica (2025); evidence level 3]
- It is clinically associated not only with an increased risk of developing T2DM, but also with accelerated atherosclerosis driven by chronic inflammation and vascular endothelial dysfunction, conferring a significantly increased cardiovascular risk []. [Geddo Federica (2025); evidence level 3]
- The first step in the management of MetS is lifestyle modification, with the adoption of a healthy diet and regular physical activity. [Geddo Federica (2025); evidence level 3]
- Dysregulation of this axis contributes to hypercholesterolemia and cardiometabolic risk, beyond classical cholesterol synthesis pathways. [Uberti F (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources